The use of classical smallpox vaccines based on vaccinia virus (VV) is associated with severe complications in both naive and immune individuals. Modified vaccinia virus Ankara (MVA), a highly attenuated replication-deficient strain of VV, has been proven to be safe in humans and immunocompromised animals, and its efficacy against smallpox is currently being addressed. Here we directly compare the efficacies of MVA alone and in combination with classical VV-based vaccines in a cynomolgus macaque monkeypox model. The MVA-based smallpox vaccine protected macaques against a lethal respiratory challenge with monkeypox virus and is therefore an important candidate for the protection of humans against smallpox.

Animals, Antibodies, Viral/blood, Disease Models, Animal, Humans, Immunization, Lung/pathology/virology, Macaca fascicularis, Monkeypox virus/immunology/*pathogenicity, Monkeypox/pathology/*prevention & control/virology, Respiratory Tract Infections/pathology/*prevention & control/virology, Skin/pathology/virology, Smallpox Vaccine/administration & dosage/*immunology, T-Lymphocytes/immunology, Vaccinia virus/genetics/*immunology
dx.doi.org/10.1128/JVI.79.12.7845-7851.2005, hdl.handle.net/1765/13812
Journal of Virology
Free full text at PubMed
Erasmus MC: University Medical Center Rotterdam

Stittelaar, K.J, van Amerongen, G, Kondova, I, van Lavieren, R.F, Pistoor, F.H, Niesters, H.G.M, … Kuiken, T. (2005). Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus. Journal of Virology, 79(12), 7845–7851. doi:10.1128/JVI.79.12.7845-7851.2005